Clinical effectiveness and tolerability of Celery seed and Boswellia serrata extract in osteoarthritis

Dr. Anish Desai, Dr. Parshuram Shendge, Dr. Sunaina Anand and Dr. Sreeni Nair

DOI: https://doi.org/10.22271/ortho.2022.v8.i2d.3143

Abstract

Background: Osteoarthritis (OA) is a common chronic articular degenerative disease marked by articular cartilage degradation, synovial inflammation/immunity, and subchondral bone lesion, among other symptoms. The disease affects 2–6% of the global population, and its prevalence increases with age, reaching 40% in people over the age of 70. Recently, there has been a surge of interest in using nutraceuticals to treat or prevent OA. Celery seed extract & Shallaki extracts (Boswellia serrata) effectively prevent cardiovascular disease, urinary tract infection, gout, and improve blood pressure. Experimental results indicate that both these extracts have anti-inflammatory properties.

Aim: The current real-world evidence study was conducted to investigate the effectiveness of Celeract Advance Tablet in OA patients.

Methods: A total of 1236 patients were enrolled in the study. All patients received Celeract Advance Tablet for 90 days. Clinical assessment of symptoms included palpation tiredness, mobility limitation, joint crepitus, swelling and redness. Osteoarthritis symptoms were measured using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), Total European Quality of Life–5 Dimensions and visual analogue scale (VAS).

Results: After 90 days treatment with Celeract Advance Tablet, WOMAC score reduced significantly from 62.64 + 20.47 to 17.22 + 17.59 (p< 0.05). For Total European Quality of Life–5 Dimensions (EQ-5D) score significantly improved from 38.76 + 8.10 to 69.13 + 8.60 (p< 0.05). From the baseline, 78.35% improvement in EQ-5D was observed in patients treated for three months. After 90 days, VAS score for pain significantly reduced from 8.07 + 5.38 to 1.78 + 4.46 (P< 0.05) after 90 days in OA patients. No major adverse reactions were reported.

Conclusion: The current study revealed that the Celeract Advance tablet effectively improves joint pain, stiffness, physical function and quality of life in OA patients.

Keywords: Osteoarthritis, Celery seed extract, Shallaki extracts, anti-inflammatory, NSAIDs, Apiaceae

Introduction

Osteoarthritis (OA) is a chronic pain condition affecting an individual's quality of life. OA is the most frequent cause of musculoskeletal pain [1]. In geriatric patients above 60 years of age, the prevalence of OA is more in men (10%) than women (13%). About 10-15% of geriatric patients show signs and symptoms of OA, with a higher prevalence in women compared to men. In India, the prevalence of OA is higher in the rural population (56.6%) than urban (32.6%). Due to lifestyle changes, the Asian population is highly exposed to the risk of knee osteoarthritis compared to Europeans and Americans [2,3,4]. The pain in osteoarthritis is caused by multiple factors driven by nociceptive and neuropathic mechanisms, along with abnormal pain pathways of the peripheral and central nervous system (CNS). Inflammation in the joint initiates a cascade of events which leads to increased sensitivity of nociceptive primary afferent neurons, peripheral sensitization, and hyper-excitability of the nociceptive neurons in the CNS [5].

Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective in the management of arthritic stiffness and other rheumatic diseases [6]. Although NSAIDs are recommended by clinical guidelines for managing pain and inflammation in OA (first-line treatment), NSAIDs show various adverse effects, including cardiovascular, renal, hepatic and gastrointestinal [6]. A celery seed extract has anti-inflammatory, analgesic, and gastro-protective properties.
Celery preparations have been used extensively since ancient
times as natural therapies for the management of acute and
chronic painful or inflammatory conditions [7]. The celery
plant (Apium graveolens) is an indigenous plant from the
family Apiaceae. The plant has a broad spectrum of use as an
aphrodisiac, anthelmintic, carminative, diuretic, emmenagogue, laxative, antispasmodic sedative, stimulant, and
toxin [8].

Boswellia serrata, also known as Shallaki, is a tropical plant
in the Burseraceae family. They are flowering plants of
medium size, both trees and shrubs. The fragrant resin
produced by the plant is used to make frankincense. Boswel-
li is widely used in traditional medicine and is an essential
component of ayurvedic medicine. Different studies showed
that Boswellia extract and its components possess
pharmacological properties such as antioxidant, anti-
inflammatory and anti-tumor action. It also exerted a positive
effect on aging, diabetes, cardiovascular and neurodegenerative disease [9].

The current study was conducted to evaluate the efficacy of
Celeract Advance Tablet in OA patients.

Methods
Study Design
A multicenter, Prospective, real-world evidence study of
Tablet Celeract Advance™ (manufactured by Wallace
Pharmaceuticals Pvt. Ltd.) was conducted to evaluate the
effectiveness and tolerability in osteoarthritis patients.

Settings and participants
Patients aged between 19 to 75 years with the clinical
diagnosis of osteoarthritis of the knee based on the American
College of Rheumatology (ACR) criteria and at least
moderate pain in the knee (rated at 5 or greater by the subject
on a visual analog scale) during the most painful knee
movement during the last month and inadequately controlled
with NSAIDs were recruited for the study.

Patients who had uncontrolled diabetes, hypertension, hepatic
disorder, pregnant & lactating women, and acute joint trauma
of the knee were excluded from the study.

Study intervention
During the study, the enrolled subjects were treated with
Celeract Advance Tablet [Celery Seeds (Ajamoda Extract)
250 mg and Shallaki Extract (Boswellia serrata) 300 mg]
twice daily for three months. Patients were advised not to
consume other ayurvedic, herbal, and homeopathic treatments
during the study period. The record of concomitant
medication was maintained during the study.

Outcome and follow up
The primary objective was to evaluate the OA symptoms,
WOMAC score, and pain during the study. Pain on palpation,
limited mobility, joint crepitus, edema, and redness were all
graded on a 4-point scale (0 = not at all, 1 = mild, 2 =
moderate, 3 = severe). The Western Ontario and McMaster
Universities (WOMAC) osteoarthritis index was used to
quantify the severity of osteoarthritis symptoms, with a higher
WOMAC score indicating more severe symptoms. The
subjects rated their discomfort on a 10-mm visual analog
scale (VAS). On days 0, 30, 60, and 90, the WOMAC, pain,
and OA symptoms were evaluated. On day 90, the patient's
global assessment and the physician's global assessment were
evaluated.

Statistical Analysis
Demographic data were analyzed using descriptive statistics.
The Difference in clinical response before and after the
treatment was assessed for normal distribution using the
Kolmogorov Smirnov test. The paired Student's t-test was
also used. For distribution-free data, the Mann Whitney U test
was used. All tests were carried out at 5% significance.

Results
During the study, a total of 1236 patients were enrolled based
on inclusion and exclusion criteria, comprising 504 (41%) males and 732 (59%) females. The mean age of the subject
was 54.22 years, and 37.73% of patients belong to the age
group above 50 years. All the subjects selected during the
study subjects received Celeract Advance Tablet twice daily
for three months.

Primary Outcome Measures
WOMAC score
At the baseline, the mean WOMAC combined score was
62.64 + 20.47 (p < 0.05), which was reduced significantly to
17.22 + 17.59 (p < 0.05) at the end of the study. From the
baseline, 72.50% improvement in WOMAC score was
observed in the patients after treatment with Celeract Advance
Tablet (Figure 1).

Further sub-group analysis shows 34.90% of patients had
excellent improvement, 25.83% and 20.81% of patients had
marked and moderate improvement respectively in WOMAC
score after 90 days of treatment with Celeract Advance Table-
(MCMC™

Table 1). The improvement in WOMAC score of OA
patients was observed within a month after treatment with
Celeract Advance Tablet™
Fig 1: Change in WOMAC score during the treatment

Table 1: Overall effect on WOMAC score

<table>
<thead>
<tr>
<th>Overall Effect WOMAC</th>
<th>No of Patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excellent improvement (&gt;90%)</td>
<td>431</td>
<td>34.90%</td>
</tr>
<tr>
<td>Marked improvement (75-89%)</td>
<td>319</td>
<td>25.83%</td>
</tr>
<tr>
<td>Moderate improvement (51-74%)</td>
<td>257</td>
<td>20.81%</td>
</tr>
</tbody>
</table>

Total European Quality of Life–5 Dimensions (EQ-5D) Score: After 90 days of treatment with Celeract Advance Tablet total ED-5D score significantly improved from 38.76 + 8.10 to 69.13 + 8.60 (p < 0.05). From the baseline, 78.35% improvement was observed in patients treated for three months (Figure 2).

Excellent improvement was observed in 37.09% of patients, 27.45%, and 21.30% of patients had marked and moderate improvement in total EQ-5D score (Table 2). The total EQ-5D score increased significantly after three months of treatment [38.76 + 69.13 to 69.13 + 8.60 (p < 0.05)].

Fig 2: Change in Total EQ 5D score during the treatment

Table 2: Overall effect on Total EQ 5D score

<table>
<thead>
<tr>
<th>Overall Effect TOTAL EQ 5D</th>
<th>No of Patients</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>Excellent Improvement (&gt;90%)</td>
<td>458</td>
<td>37.09%</td>
</tr>
<tr>
<td>Marked Improvement (75-89%)</td>
<td>339</td>
<td>27.45%</td>
</tr>
<tr>
<td>Moderate Improvement (51-74%)</td>
<td>263</td>
<td>21.30%</td>
</tr>
</tbody>
</table>

Secondary Outcome measures

VAS score

VAS score is generally used to determine the intensity of pain in patients. Celeract Advance Tablet treatment reduced VAS score from 8.07 + 5.38 to 1.78 + 4.46 (P < 0.05) after 90 days in OA patients (figure 3).

Furthermore, the sub-analysis evaluation revealed excellent improvement of VAS score in 37.41% of patients, 27.94% and 21.78% of the patients showed marked and moderate improvement, respectively (Table 3).
Discussion
This Multicenter, Prospective study investigated the effectiveness of Celeract Advance Tablet in patients with osteoarthritis. The administration of Celeract Advance Tablet for three months lead to the improvement in WOMAC score, total EQ-5D score, and VAS score in OA patients. The improvement in OA was observed a month after initiation of treatment with Celeract Advance Tablet. The results obtained in the current study are in line with a similar published open-label study involving adult patients with chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis. In the study, patients received 250 mg tablets containing standardized celery seed extract twice daily for 8 weeks. Excellent improvement in the reduction of joint swelling was seen in 45% of the patients; 46% of the patients showed good improvement in reducing grinding/cracking knees on movement; 42% showed excellent efficacy in reducing the restriction of movements; 49% showed good improvement in reduction of morning stiffness and pain during movements and 57% showed good improvement in reducing the difficulty in doing daily chores. The administration of celery seed extract tablets twice daily for 8 weeks was effective and well-tolerated in OA patients [10]. Celery preparations have been used majorly for the management of acute and chronic inflammatory conditions. Celery Seed Extract (CSE) has similar efficacies as aspirin, ibuprofen, and naproxen in suppressing arthritis in a model of polyarthritis and has also been proven as an analgesic in two experimental models. CSE also protect against and/or reduce gastric irritation caused by NSAIDs, and act synergistically with them in reducing inflammation [7]. Celery seed inhibits COX 1 and 2 and prostaglandin synthesis. Pre-clinical studies have shown similar efficacy of celery seed extract and ibuprofen in reducing inflammation. A 12-week study was conducted in OA patients. The patients received a celery extract tablet twice daily. The study showed that after 3 weeks of the treatment, there was a 68% reduction in pain scores, with 100% pain relief in some patients. Those who continued treatment for 6 weeks showed maximum benefits. Another study was conducted with patients receiving the higher dose of the extract (75 mg). The study reported statistically significant reductions in pain scores, mobility, and quality of life. Another clinical study in patients with OA found 75% relief in pain in patients receiving the celery seed extract as compared to placebo [7, 8, 10]. 3-O-Acetyl-11-keto-beta-boswellic acid (AKBA) in Boswellia serrata extract contributes to its anti-inflammatory action by inhibiting 5-lipoxygenase. A meta-analysis of 28 studies found that Boswellia serrata extract is both safe and effective in patients with OA [11].

Conclusion
This is the first clinical evidence generation study that supports the potential use of Celeract Advance, a novel combination of Celery seed (Ajamoda) extract and Sallaki (Boswellia serrata) extract as an adjuvant in the management of knee OA. Celeract Advance helps in the improvement of joint pain, stiffness and function, thus leading to a better quality of life in patients with OA.

Acknowledgments
The authors thank all the study investigators, study coordinators, and other study personnel who participated in the study, for their contributions.

References
7. Powanda MC, Whitehouse MW, and Rainsford KD. Celery Seed and related extracts with antiarthritic, antiulcer, and antimicrobial activities. Prog Drug Res. 2015;70:133-53